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Introduction
Parkinson’s disease is the second most common 
neurodegenerative disease and is characterised by 
bradykinesia with resting tremor, stiﬀ ness, and gait 
disturbance, and a range of non-motor features. It 
involves the aggregation of α-synuclein as Lewy bodies 
and Lewy neurites in many motor and non-motor brain 
areas. The population prevalence is estimated at 0·3%, 
but increases with age, rising to 1–2% in people older 
than 60 years and 3–4% in those older than 80 years.1 The 
median age of onset is around 60 years.2
The identiﬁ cation of rare highly penetrant mutations 
in genes causing familial Parkinson’s disease has 
substantially improved our understanding of the 
pathogenesis of this complex and common disorder.2 
Simultaneously, our understanding of the idiopathic 
form of the disease has been enhanced by ﬁ ndings from 
large genome-wide association studies.3–8
Microdeletions at chromosome 22q11.2 are the most 
frequent known interstitial deletions found in human 
beings, occurring in about 25 in 100 000 livebirths.9 
These well-characterised deletions are inherited from 
an aﬀ ected parent in 5–10% of cases and occur de novo 
in the remainder.9 About 87% of deletions span a shared 
3 Mb region that includes at least 52 known genes, 
whereas around 8% span a smaller 1·5 Mb region 
(nested within the larger 3 Mb region) that contains at 
least 31 genes.10 The remainder also span the larger 
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Summary
Background Parkinson’s disease has been reported in a small number of patients with chromosome 22q11.2 deletion 
syndrome. In this study, we screened a series of large, independent Parkinson’s disease case-control studies for 
deletions at 22q11.2.
Methods  We used data on deletions spanning the 22q11.2 locus from four independent case-control Parkinson’s 
disease studies (UK Wellcome Trust Case Control Consortium 2, Dutch Parkinson’s Disease Genetics Consortium, 
US National Institute on Aging, and International Parkinson’s Disease Genomics Consortium studies), which were 
independent of the original reports of chromosome 22q11.2 deletion syndrome. We did case-control association 
analysis to compare the proportion of 22q11.2 deletions found, using the Fisher’s exact test for the independent case-
control studies and the Mantel-Haenszel test for the meta-analyses. We retrieved clinical details of patients with 
Parkinson’s disease who had 22q11.2 deletions from the medical records of these patients.
Findings We included array-based copy number variation data from 9387 patients with Parkinson’s disease and 
13 863 controls. Eight patients with Parkinson’s disease and none of the controls had 22q11.2 deletions (p=0·00082). 
In the 8451 patients for whom age at onset data were available, deletions at 22q11.2 were associated with Parkinson’s 
disease age at onset (Mann-Whitney U test p=0·001). Age at onset of Parkinson’s disease was lower in patients 
carrying a 22q11.2 deletion (median 37 years, 95% CI 32·0–55·5; mean 42·1 years [SD 11·9]) than in those who did 
not carry a deletion (median 61 years, 95% CI 60·5–61·0; mean 60·3 years [SD 12·8]). A 22q11.2 deletion was 
present in more patients with early-onset (p<0·0001) and late-onset Parkinson’s disease (p=0·016) than in controls, 
and in more patients with early-onset than late-onset Parkinson’s disease (p=0·005). 
Interpretation Clinicians should be alert to the possibility of 22q11.2 deletions in patients with Parkinson’s disease 
who have early presentation or features associated with the chromosome 22q11.2 deletion syndrome, or both.
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3 Mb region, but with diﬀ erent breakpoints. 10 The 
homogeneity of the deletion breakpoints is largely due 
to the presence of blocks of genomic sequence known 
as low copy repeats (LCRs) at the breakpoints of each 
deleted region.10 The LCRs are believed to act as targets 
for anomalous non-allelic homologous recombi nation 
during meiosis, thereby generating chromosomal 
rearrangements.
Deletions at 22q11.2 have been associated with a 
heterogeneous range of clinical syndromes, which 
include DiGeorge syndrome and velocardiofacial 
syndrome and, as such, they are typically grouped 
together as chromosome 22q11.2 deletion syndrome. As 
would be expected from the product of this diverse range 
of clinical syndromes, the phenotype of chromosome 
22q11.2 deletion syndrome is complex and typically 
includes psychiatric, craniofacial, immunological, and 
cardiovascular defects.
In 2013, by following up clinical case reports of four 
individuals who carried a hemizygous deletion at 
chromosome 22q11.2 and also had parkinsonism,11–13 
Butcher and colleagues14 identiﬁ ed an additional four 
patients, one of whom had been reported previously,13 
with Parkinson’s disease in a cohort of 68 adults with 
22q11.2 deletion syndrome aged 35 years and older. The 
patients had no family history of Parkinson’s disease, 
genetic screening did not identify any known pathogenic 
mutations related to Parkinson’s disease, and post-
mortem analysis of three of four patients revealed classic 
loss of midbrain dopaminergic neurons, with two having 
α-synuclein-positive Lewy bodies. Together, these data 
suggest that microdeletions at 22q11.2 might confer an 
increased risk of Parkinson’s disease.
These previous studies focused on identiﬁ cation of 
Parkinson’s disease in carriers of the 22q11.2 deletion. In 
this study, we set out to establish the frequency of 
deletions spanning the 22q11.2 locus in idiopathic 
Parkinson’s disease. 
Methods
Study design and participants
We used data from four independent genome-wide 
association studies of Parkinson’s disease that had been 
analysed for copy number variants (CNVs). The details 
of all samples from the four studies—namely, the UK 
Wellcome Trust Case Control Consortium 2 (WTCCC2) 
Parkinson’s disease, Dutch Parkinson’s Disease 
Genetics Consortium, US National Institute on Aging 
(NIA), and International Parkinson’s Disease Genomics 
Consortium (IPDGC), have been described previously.3–8 
Most cases were recruited using UK Brain Bank 
Criteria, with modiﬁ cation in the IPDGC NeuroX 
study15 to allow patients with family history to be 
included, and for one subset (contributed by Academic 
Medical Center Amsterdam) of the Dutch cohort, the 
criteria by Gelb and colleagues were used.16 The US 
NIA controls were from the Neurogenetic Repository at 
the Coriell Institute for Medical Research, which 
excluded people with schizophrenia and other neuro-
logical diseases (appendix A); unscreened population 
Research in context
Evidence before this study
Deletion at 22q11.2 is one of the most common deletions 
found in human beings and is one of the strongest identiﬁ ed 
genetic risk factors for schizophrenia. Findings from previous 
case reports and one case study have suggested a 
22q11.2 deletion might be associated with Parkinson’s disease. 
In comparison with studies of 22q11.2 deletions in 
schizophrenia, so far, no data from large Parkinson’s disease 
studies exist regarding the potential role of 22q11.2 deletion on 
risk of Parkinson’s disease. We screened data from independent 
genome-wide association studies to establish the frequency of 
22q11.2 deletions in patients with Parkinson’s disease.
Added value of this study
We provide evidence that deletions at 22q11.2 increase the risk of 
Parkinson’s disease, particularly early-onset Parkinson’s disease 
(onset age <45 years). An estimation of increased risk of early-
onset Parkinson’s disease, conferred by deletions at 22q11.2, is 
about a 20-times increase compared with the general 
population (assuming the proportion of carriers of a 22q11.2 
deletion is 0·024%). This risk is comparable to the odds ratio for 
development of schizophrenia. The frequency of 
22q11.2 deletion was signiﬁ cantly higher in Parkinson’s disease 
overall (0·09%) than in controls, but was higher in early-onset 
(0·49%) than in late-onset (0·04%) Parkinson’s disease. 
Presenting features of Parkinson’s disease in 22q11.2 deletion 
carriers are similar to those in patients with Parkinson’s disease in 
general, other than an earlier age of onset. Outcomes might be 
less favourable, with more rapid deterioration and mortality.
Implications of all the available evidence
Clinicians should bear this uncommon 22q11.2 deletion in 
mind when a patient presents with early-onset Parkinson’s 
disease. Carriers of a 22q11.2 deletion are prone to many other 
potential comorbidities, and clinicians should actively 
investigate for these comorbidities when managing a patient 
with a 22q11.2 deletion and Parkinson’s disease. Therefore, the 
22q11.2 deletion links two diﬀ erent neuropsychiatric disorders: 
schizophrenia and Parkinson’s disease. Whether there is a single 
common pathogenic pathway or whether separate genetic 
defects within the 22q11.2 deletion contribute to the diﬀ ering 
phenotypes remains unclear. Nevertheless, a potential link 
through catechol-O-methyltransferase is plausible and should 
be investigated further. 
Articles
www.thelancet.com/neurology   Vol 15   May 2016 587
Neurogenetics, National 
Institute on Aging, Bethesda, 
MD, USA (M A Nalls PhD, 
A B Singleton PhD); and UCL 
Genetics Institute, London, UK 
(V Plagnol PhD)
Correspondence to:
Prof Nicholas W Wood, 
Department of Molecular 
Neuroscience, UCL Institute of 
Neurology, London WC1N 3BG, 
UK
n.wood@ucl.ac.uk
or
Dr Nigel M Williams, Institute of 
Psychological Medicine and 
Clinical Neurosciences, MRC 
Centre for Neuropsychiatric 
Genetics and Genomics, Cardiff 
University School of Medicine, 
Cardiff University, 
Cardiff CF24 4HQ, UK
williamsnm@cf.ac.uk
See Online for appendix
controls were used in the other studies. Only patients 
and controls of European descent and unrelated were 
included. 
The original studies3–8 received approval from the 
relevant ethics committees, as previously published. 
Patients and controls or their legal representatives 
provided informed consent before recruitment..
Procedures
Samples were genotyped using the Illumina 660,3–5,8 
Illumina 1·2M Duo,3–5 Illumina550,6 Illumina240S and 
Illumina317K,6 or the NeuroX arrays7 (Illumina, San 
Diego, CA, USA). We did CNV analysis for all autosomes 
using standard protocols, as described previously.17 
Brieﬂ y, CNVs (minimum of ten single nucleotide 
polymorphisms) were identiﬁ ed using PennCNV 
(2011Jun16 version) and included GC content as a 
covariate in the PennCNV statistical model.18 Derivative 
of LogR ratio (LRR; LRR_SD) and derivative of B-allele 
frequency (BAF; BAF_SD) were generated by PennCNV; 
samples with an LRR_SD greater than 0·30, a BAF_SD 
greater than 0·15, or a number of CNVs 3 SDs above the 
mean CNV number of the case or control groups were 
excluded. Because some large CNVs can be erroneously 
split by CNV identifying algorithms, we merged CNVs 
larger than 100 kb that occurred in an individual if the 
gap was less than 50% of the entire length of the newly 
merged CNV. LRR and BAF of the newly created CNV 
were visually inspected before acceptance for inclusion. 
The reported region typically deleted in chromosome 
22q11.2 deletion syndrome is usually 3 Mb and spans 
from around 18·8 Mb to 21·8 Mb (hg19) on 
chromosome 22 or, less commonly, is 1·5 Mb (around 
18·9 Mb to 20·4 Mb) and at the centromeric part of the 
3 Mb region.10 To ensure that our CNV selection strategy 
identiﬁ ed atypical deletions at this locus, we selected all 
deletions identiﬁ ed in the cases and controls that 
spanned the region encompassed by the 1·5 Mb deletion 
by at least 60%. To validate the deletions, we used a 
customised array (CytoSure 15k-Array, Agilent-based 
Array Comparative Genomic Hybridisation, Oxford 
Gene Technology, Oxford, UK). 
Statistical analysis
 We compared the proportions of chromosome 22q11.2 
deletions between cases with Parkinson’s disease and 
controls from four independent Parkinson’s disease 
case-control studies. For each independent case-control 
study, we compared the two groups using the Fisher’s 
exact test (two sided). For the meta-analysis of the four 
studies (ten studies when we split the IPDGC study into 
seven subgroups), we used the Mantel-Haenszel exact 
test (two sided) to avoid the Simpson’s paradox.19,20 A 
classic description of Simpson’s paradox is when a 
pattern that appears in diﬀ erent groups of data disappears 
or reverses when these groups are combined. This 
situation can occur because of other hidden confounding 
variables not controlled by simple combination, leading 
to a paradoxical result. We also tested the contribution of 
each independent study to our meta-analysis by doing a 
sensitivity analysis, in which we sequentially excluded 
each independent study before repeating the meta-
analysis. Rare mutations that confer an increased risk of 
Parkinson’s disease occur typically in patients with 
Parkinson’s disease with an earlier age at onset.21  To 
investigate the relation between 22q11.2 deletions and 
age at onset of disease, we compared the distribution of 
age at onset between deletion carriers and non-carriers 
with a Mann-Whitney U test. Patients are generally 
regarded as having early-onset Parkinson’s disease if they 
have an age at onset younger than 45 years.22 The 
proportion of 22q11.2 deletions found in patients with 
early-onset and late-onset Parkinson’s disease was 
compared with proportion in controls and also between 
patients with early-onset and late-onset Parkinson’s 
disease using Fisher exact test and Mantel-Haenszel 
exact test. To estimate the odds ratio of Parkinson’s 
disease in 22q11.2 deletion carriers, we assumed a 
population prevalence of 22q11.2 deletions of 0·024%,23 
which is close to 25 in 100 000 livebirths.9 One-sided 
p value was also added in footnotes of result tables to 
enable readers who wish to compare with some previous 
CNV studies using one-sided test.
We did all statistical analyses in SPSS (version 20.0.0) 
and R (version 3.12). p values of 0·05 or lower were judged 
to be statistically signiﬁ cant.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. KYM, US, NMW, and NWW had 
full access to all the data in the study and the 
corresponding authors had ﬁ nal responsibility for the 
decision to submit for publication.
Results
9387 patients with Parkinson’s disease and 13 863 controls 
were included from the four case-control studies. The 
disease age at onset was available for 8451 (90%) of 
9387 patients with Parkinson’s disease. Age at onset data 
were available for all patients carrying the 22q11.2 
deletion.
The most common deletion associated with 
chromosome 22q11.2 deletion syndrome spans about 
3 Mb (around hg19 chromosome 22: 18·8–21·8 Mb) and 
is ﬂ anked by LCRs A–D (ﬁ gure). We identiﬁ ed eight 
unrelated patients with Parkinson’s disease who carried 
the most common chromosome 22q11.2 deletion 
syndrome (3 Mb) deletion from three independent 
Parkinson’s disease studies, with none detected in the 
fourth, smallest study (US NIA; ﬁ gure; table 1). Using the 
customised CytoSure 15k-Array,  we validated all the 3 Mb 
deletions in the UK groups (UK 1 and UK 2, data not 
shown). These data conﬁ rmed the deletion breakpoint 
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ﬁ ndings from the Illumina array. We did not replicate the 
validation in other studies because the validation in UK 
samples showed convincing results using the Illumina 
array. Analysis of the largest independent study (UK 
WTCCC2, assuming the IPDGC NeuroX study is a meta-
analysis of studies) revealed a pattern of enrichment of 
22q11.2 deletion in patients with Parkinson’s disease 
(p=0·059; table 1). A similar pattern was noted when the 
IPDGC NeuroX study was classed as a homogeneous 
study, using the Fisher’s exact test (table 1). In the 
combined meta-analyses of all independent samples 
(9387 patients with Parkinson’s disease and 
13 863 controls; table 1), 22q11.2 deletions were associated 
with Parkinson’s disease, both when the IPDCG NeuroX 
study was classed as one subgroup (four-subgroup 
analysis p=0·00056) and when each group within that 
study was classed as a separate subgroup (ten-subgroup 
analysis; p=0·00082). Although we only identiﬁ ed 3 Mb 
deletions and did not identify any of the infrequent but 
well-characterised 1·5 Mb deletions that typically span 
LCRs A–B, in a post-hoc inspection of CNVs at this locus, 
we identiﬁ ed one patient carrying an atypical 726 kb 
deletion spanning LCRs B–D (UK 3; ﬁ gure). Association 
data were also signiﬁ cant after inclusion of this rare 
deletion (four-subgroup analysis p=0·00014; ten-subgroup 
analysis p=0·00020; appendix); however, because we were 
uncertain of the relation between this rare deletion and 
chromosome 22q11.2 deletion syndrome, we excluded it 
from our statistical analyses.  Because the UK 3 deletion 
was not considered a chromosome 22q11.2 deletion 
syndrome, DNA was not sent for replication in 
comparative genomic hybridisation . Other than the 
22q11.2 deletion, no other recurrent CNVs of moderate to 
large size (>500 kb) were found in these eight patients.
Findings from the sensitivity analysis revealed that 
association with deletions at 22q11.2 remained signiﬁ cant 
after the systematic exclusion of each independent study 
from the meta-analysis (all p≤0·016; appendix). 
In the 8451 patients for whom age at onset data were 
available (table 2), age at onset of Parkinson’s disease 
was lower in patients carrying a 22q11.2 deletion (median 
37 years, 95% CI 32·0–55·5; mean 42·1 years [SD 11·9]) 
than in those who did not carry a deletion (median 
61 years, 95% CI 60·5–61·0; mean 60·3 years 
[SD 12·8]; p=0·001). Patients are generally regarded as 
having early-onset Parkinson’s disease if they have an 
age at onset younger than 45 years.24 Of the 1014 patients 
with Parkinson’s disease with age at onset younger than 
45 years, ﬁ ve (0·49%) had 22q11.2 deletions, compared 
with three (0·04%) of 7437 with an age at onset of 
45 years or older (late-onset Parkinson’s disease; four-
subgroup analysis p=0·0007; ten-subgroup analysis 
p=0·005; table 3). A 22q11.2 deletion was present in 
more patients with early-onset (ten-subgroup analysis 
p<0·0001) and late-onset Parkinson’s disease (p=0·016) 
than in controls (table 3).  The ﬁ ndings were similar 
when we deﬁ ned early-onset Parkinson’s disease as 
onset younger than 50 years post-hoc (appendix A).  The 
frequency of 22q11.2 deletions in controls (0%) is lower 
than the expected population frequency of 0·024% that 
was reported from a study of large cohorts.21 To address 
the possible bias, we estimated that at the population 
frequency of 0·024%, we expected to detect around three 
deletions at 22q11.2 in our control sample of 
13 863 people. Association analysis revealed that, even 
when using this conservative estimate, the excess of 
22q11.2 deletions in patients with early-onset Parkinson’s 
disease was signiﬁ cant (p<0·0001; appendix).
With an estimated one in four carriers of the 22q11.2 
deletion with schizophrenia, having a hemizygous 
deletion at 22q11.2 is one of the strongest known risk 
factors for development of the disease.25 Moreover, 
 although in a large study the proportion of patients with 
schizophrenia who had a 22q11.2 deletion was 0·29%,26 
studies using community catchment populations have 
yielded a proportion of 0·98%,27 and ﬁ ndings from a 
review suggested a proportion of up to 2·4%.25 In 
comparison, in the present study, we found  that 0·49% 
of patients with idiopathic early-onset Parkinson’s 
disease  had 22q11.2 deletions. Post hoc, we attempted an 
Window position
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Deletions identified in Parkinson’s disease cohorts
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Figure: Genomic location of the 22q11.2 deletions found in the eight patients with Parkinson’s disease and location of the low copy repeat regions
UK3 represented an atypical deletion of uncertain relation to 22q11.2 deletion syndrome and was not considered here. Figure drawn using the UCSC Genome Browser.24 
For the UCSC Genome Browser 
see http://genome.ucsc.edu
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estimation of increased risk of early-onset Parkinson’s 
disease, conferred by deletions at 22q11.2, which is a 
20-times increase compared with the general population 
(assuming the proportion of carriers of a 22q11.2 deletion 
is 0·024%; appendix A). However, in view of the small 
number of cases (ﬁ ve) and the large CIs, this ﬁ nding 
should be considered an estimate of the conferred risk.
 Table 4 describes the clinical features of the patients 
with Parkinson’s disease who had a 22q11.2 deletion. 
The eight patients fulﬁ lled the UK Brain Bank Criteria 
for Parkinson’s disease, had asymmetry in onset of 
motor symptoms and tremor (seven of seven patients 
with assessment records available), developed 
bradykinesia and rigidity during the disease course (six 
of six patients with available data), and most had a good 
initial response to levodopa or dopamine agonist 
treatment (ﬁ ve of six). No structural abnormalities were 
noted in all three patients for whom MRI scan data were 
available (IPDGC NeuroX 4 and 5, and UK 1). Dopamine 
transporter scans were abnormal in all four patients for 
whom these data were available, with asymmetric 
deﬁ cits in two (UK 1 and Dutch 1) and a symmetrical 
decrease in the other two (IPDGC NeuroX 4 and 5), who 
had longer disease duration. None of the six patients for 
whom more detailed clinical histories were available had 
interrupted aortic arch type B, truncus arteriosus, or 
tetralogy of Fallot. Patient IPDGC NeuroX 3 had a 
valvular heart lesion, with no detailed information on 
the nature of cardiac anomaly. Mitral valve prolapse was 
discovered after Parkinson’s disease was diagnosed in 
patient IPDGC NeuroX 5. Three patients had depression 
before diagnosis of Parkinson’s disease (Dutch 1, UK 2, 
and IPDGC NeuroX 4: NeuroX4 might be reactive 
depression). None of the eight patients had schizophrenia 
diagnosed before onset of Parkinson’s disease. Two 
patients had cleft palate or oropharyngeal malformation 
diagnosed before onset of Parkinson’s disease (IPDGC 
NeuroX 1 and 5, respectively) and one was found to have 
biﬁ d uvula during investigations for dysphagia after 
diagnosis of Parkinson’s disease. IPDGC NeuroX 4 had 
hypo calcaemia. Two of the eight patients died at a young 
age (IPDGC NeuroX 2 and UK 2, at 51 and 56 years old 
respectively). 
So far, no data exist on the prevalence of chromosome 
22q11.2 deletion syndrome in Parkinson’s disease. The 
prevalence of early-onset Parkinson’s disease had been 
quoted to be about 3–5% of all Parkinson’s disease 
cases.28 In the Cardiﬀ  community survey,29,30 the estimated 
prevalence of Parkinson’s disease was 140 per 
100 000 people, with 3·6% of patients developing the 
disease before age 45 years, which is comparable to the 
4·2% reported in Canada.29,30 Assuming 4% of all patients 
with Parkinson’s disease have early-onset disease and 
since about 0·5% had a 22q11.2 deletion in the present 
study, we estimate the prevalence of early-onset 
Parkinson’s disease with a 22q11.2 deletion to be 
0·028 per 100 000 people (140 × 4% × 0·5%).
Discussion
In this study, we provide evidence that 22q11.2 deletions 
are associated with an increased risk of Parkinson’s 
disease. In a previous observational study, an increased 
frequency of Parkinson’s disease was reported in patients 
with chromosome 22q11.2 deletion syndrome compared 
Patients with 
Parkinson’s disease
Controls p value
Number 
of patients
Number with 
22q11.2 
deletion (%)
Number Number 
with 22q11.2 
deletion
Two-sided 
Fisher’s 
exact test
Two-sided 
Mantel-
Haenszel test
Studies
US NIA 593 0 726 0 1·00 ··
UK WTCCC2 1592 2 (0·13%) 4939 0 0·059 ··
Dutch Parkinson’s 
Disease Genetics 
Consortium
740 1 (0·14%) 1996 0 0·271 ··
IPDGC NeuroX 6462 5 (0·08%) 6202 0 0·063* 0·069†
UK 804 2 (0·25%) 684 0 0·50 ··
USA 2069 0 2652 0 1·00 ··
France 564 2 (0·35%) 479 0 0·50 ··
Germany 1298 1 (0·08%) 883 0 1·00 ··
Greece 736 0 891 0 1·00 ··
Netherlands 316 0 447 0 1·00 ··
PPMI or other 675 0 166 0 1·00 ··
 Meta-analyses
Four subgroups 
(IPDGC NeuroX 
counted as one 
subgroup)
9387 8 13 863 0 ·· 0·00056
Ten subgroups (each 
group in 
IPDGC NeuroX 
counted separately)
9387 8 13 863 0 ·· 0·00082
p values for the one-sided Fisher’s exact tests were the same as for the two-sided tests, apart from for IPDGC NeuroX, 
which was p=0·035. p values for the one-sided Mantel-Haenszel tests were the same as for the two-sided tests. 
IPDGC=International Parkinson’s Disease Genomics Consortium. NIA=National Institute on Aging. PPMI=Parkinson’s 
Progression Marker Initiative. WTCCC2=Wellcome Trust Case Control Consortium 2. *Assuming the populations were 
non-heterogeneous and adding the number of cases or controls together. †Treating IPDGC NeuroX as a 
seven-subgroup meta-analysis. 
Table 1: Association studies of deletions at chromosome 22q11.2 
Patients with Parkinson’s 
disease
Patients with Parkinson’s disease and 
known age of onset
Total With 22q11.2 deletion
Male Female Number (%)* Male Female
US NIA 593 0 0 593 (100%) 355 238
UK WTCCC2 1592 1 1 1545 (97%) 900 645
Dutch Parkinson’s Disease 
Genetics Consortium
740 1 0 714 (96%) 456 258
IPDGC NeuroX 6462 4 1 5599 (87%) 3584 2015
Total 9387 6 2 8451 (90%) 5295 3156
IPDGC=International Parkinson’s Disease Genomics Consortium. NIA=National Institute on Aging. WTCCC2=Wellcome 
Trust Case Control Consortium 2. *Percentage of total number of patients with Parkinson’s disease.
Table 2: Patients with Parkinson’s disease entered into the age at onset analysis 
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with controls.14 Herein, we report the results of the reverse 
experiment, namely pooling of data from large Parkinson’s 
disease case-control studies and assessment of the 
frequency of 22q11.2 deletion carriers. We found a 
signiﬁ cantly higher frequency of 22q11.2 deletions in both 
patients with early-onset and late-onset Parkinson’s 
disease compared with controls, and in patients with 
early-onset compared with late-onset Parkinson’s disease. 
Findings from the sensitivity analysis remained signiﬁ cant 
after the systematic exclusion of each independent study 
from the meta-analysis, which suggests that, despite the 
variation in sample size across studies, there was no 
evidence that the association was generated by a single 
study. We therefore suggest that presence of a 22q11.2 
deletion is a risk factor for Parkinson’s disease, in 
particular early-onset Parkinson’s disease.
None of the patients identiﬁ ed presented with a 
diagnosis of chromosome 22q11.2 deletion syndrome. 
With hindsight, some cases had other features suggestive 
of 22q11.2 deletion syndrome, such as hypocalcaemia, 
depression, fatigue, mental retardation, and cleft palate. 
However, cleft palate (prevalence up to one in 700)31 and 
childhood seizures (prevalence 2–4%)32 are not rare. 
Depression occurs in 40% of patients with Parkinson’s 
disease and is one of the non-motor symptoms.33 Apathy 
is found in 20–36% of patients with newly diagnosed 
Parkinson’s disease and can pre-date Parkinson’s 
disease.34 Therefore, these features would not necessarily 
be diagnostic for chromosome 22q11.2 deletion 
syndrome. One patient had a valvular heart lesion, but no 
detailed information was available. None of the six 
patients for whom more detailed clinical histories were 
available had characteristic cardiac features (interrupted 
aortic arch type B, truncus arteriosus, and Tetralogy of 
Fallout), which have been reported in over 60% of 
patients with chromosome 22q11.2 deletion syndrome.35 
One patient had mitral valve prolapse, but this is not 
associated with chromosome 22q11.2 deletion syndrome. 
The aforementioned cardiac features might be 
insuﬃ  cient to alert clinicians to the presence of  22q11.2 
deletion in the Parkinson’s disease patients.
An obvious question is whether the eight identiﬁ ed 
patients are typical cases of Parkinson’s disease. Without 
pathological conﬁ rmation of Parkinson’s disease, we 
cannot categorically exclude this possibility. However, the 
patients in this study fulﬁ lled the UK Brain Bank Criteria 
for Parkinson’s disease and had typical signs and 
symptoms of the disease. These include asymmetric 
onset of motor symptoms, and tremor, bradykinesia, and 
rigidity during the disease course. Additionally, most 
patients had a good initial response to levodopa or 
dopamine agonist treatment. The dopamine transporter 
scans available were comparable with those from patients 
with Parkinson’s disease. All these ﬁ ndings are 
Patients with EOPD 
(age of onset <45 years)
Patients with LOPD 
(age of onset ≥45 years)
Total Controls Association test p values
Number of 
patients
Number with 
22q11.2 deletion 
(%)
Number 
of 
patients
Number with 
22q11.2 
deletion (%)
Number of 
controls
Number with 
22q11.2 
deletion (%)
EOPD vs LOPD EOPD vs 
controls
LOPD vs 
controls
Studies
US NIA 121 0 472 0 593 726 0 1·0* 1·0* 1·0*
UK WTCCC2 94 1 (1·06%) 1451 1 (0·07%) 1545 4939 0 0·12* 0·019* 0·23*
Dutch Parkinson’s Disease 
Genetics Consortium
139 0 575 1 (0·17%) 714 1996 0 1·0* 1·0* 0·22*
IPDGC NeuroX 660 4 (0·61%) 4939 1 (0·02%) 5599 6202 0 0·0009*† <0·0001*† 0·443*†
UK 131 1 (0·76%) 320 1 (0·31%) 451 684 0 0·50* 0·16* 0·32*
USA 131 0 1858 0 1989 2652 0 1·0* 1·0* 1·0*
France 108 2 (1·9%) 455 0 563 479 0 0·037* 0·034* 1·0*
Germany 177 1 (0·56%) 962 0 1139 883 0 0·16* 0·17* 1·0*
Greece 46 0 642 0 688 891 0 1·0* 1·0* 1·0*
Netherlands 16 0 81 0 97 447 0 1·0* 1·0* 1·0*
PPMI or other 51 0 621 0 672 166 0 1·0* 1·0* 1·0*
Meta-analyses
Four subgroups (IPDGC 
NeuroX counted as one 
subgroup)
1014 5 7437 3 8451 13 863 0 0·0007‡ <0·0001‡ 0·023‡
Ten subgroups (each group 
in IPDGC NeuroX counted 
separately)
1014 5 7437 3 8451 13 863 0 0·005‡ <0·0001‡ 0·016‡
p values for one-sided tests were the same as for the two-sided tests. EOPD=early-onset Parkinson’s disease. IPDGC=International Parkinson’s Disease Genomics Consortium. LOPD=late-onset Parkinson’s disease. 
NIA=National Institute on Aging. PPMI=Parkinson’s Progression Marker Initiative. WTCCC2=Wellcome Trust Case Control Consortium 2. *Two-sided Fisher’s exact test. †Assuming the populations were non-
heterogeneous and adding the number of cases and controls together. ‡Two-sided Mantel-Haenszel test. 
Table 3: Comparison of deletions at 22q11.2 according to Parkinson’s disease age at onset 
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suggestive of Parkinson’s disease in these patients. The 
early age at onset, early drug-related dyskinesia and 
motor ﬂ uctuations, and cognitive and psychotic features 
associated with treatment might provide clinical clues to 
the presence of chromosome 22q11.2 deletion 
syndrome. Any additional history of orofacial anomalies 
or cognitive or psychiatric illness in patients with 
Parkinson’s disease with an early age of onset should 
also prompt clinicians to consider the possibility of 
chromosome 22q11.2 deletion. 
The ﬁ ndings from this study are important for patient 
management in early-onset Parkinson’s disease and 
insight into pathogenic mechanisms. In the investigation 
of early-onset Parkinson’s disease, the possibility of a 
22q11.2 deletion should be considered. Although the 
estimated prevalence among patients with early-onset 
Parkinson’s disease was not high (0·49%), the presence 
of a 22q11.2 deletion has direct implications for 
management, especially the identiﬁ cation and medical 
management of comorbidities.  Detailed guidelines on 
counselling for patients with 22q11.2 deletion syndrome 
have been reviewed.36–38 A few features speciﬁ c to 
chromosome 22q11.2 deletion syndrome in Parkinson’s 
disease are worth mentioning: genetic counselling 
should be provided to oﬀ spring (>90% of chromosome 
22q11.2 deletion syndrome cases are de novo) and 
appropriate guidance given for prenatal testing, if 
needed; and cognitive issues need to be considered in 
terms of managing the patient’s direct health care, 
counselling, and the implications that carrying a genetic 
defect (22q11.2 deletion) might have on family members. 
Management of comorbidities will need the input of 
specialist teams.
Two patients died at a young age (<60 years old). Two 
studies have assessed mortality in children with 
chromosome 22q11.2 deletion syndrome39,40 and only one 
has investigated mortality and sudden death among 
adults.41 By adding paediatric and adult mortality from 
previous studies,39–41 we crudely estimate survival to be 
around 75% at 40 years old and less than 65% at 50 years 
old. We were not able to establish the cause of death in 
the two patients who died at a young age. None of the 
eight patients with Parkinson’s disease and chromosome 
22q11.2 deletion had a known history of major cardiac 
abnormality or schizophrenia. Most of the cases in the 
reported adult sudden death study had either a major 
cardiac abnormality or schizophrenia.41 Hence, the 
prognosis of the patients with Parkinson’s disease and 
chromosome 22q11.2 deletion might be diﬀ erent from 
that of the patients in the sudden death study. 
Nevertheless, clinicians should still consider a cardiac 
work-up and monitor for the possibility of sudden death 
in patients with early-onset Parkinson’s disease who 
carry the 22q11.2 deletion.
We note that this higher mortality in patients with 
chromosome 22q11.2 deletion syndrome compared with 
the general population39–41 might aﬀ ect the assumed 
carrier frequency in the general population. If the actual 
population carrier frequency is lower than 0·024% 
(assumed frequency) because of the increased mortality, 
then our statistical signiﬁ cance would be more robust for 
the diﬀ erence between the deletion carrier rate in 
Parkinson’s disease detected versus the general 
population. 
Chromosome 22q11.2 deletion syndrome arises in an 
estimated 25 in 100 000 livebirths,9 and our estimated 
prevalence of early-onset Parkinson’s disease with a 
22q11.2 deletion is 0·028 per 100 000 people. By assessing 
the clinical features of our cases and reviewing the 
published work, we have come up with potential 
explanations for this diﬀ erence. First, none of the cases 
in this study were suspected to have chromosome 22q11.2 
deletion syndrome and none have had schizophrenia or a 
severe congenital heart anomaly, both of which are 
common in people with chromosome 22q11.2 deletion 
syndrome. Our recruitment of patients with Parkinson’s 
disease must have excluded most patients with 
chromosome 22q11.2 deletion syndrome with 
characteristic severe cardiac disorders or schizophrenia, 
even though this was not a planned exclusion criteria. 
Second, three of eight patients had age of onset of 
Parkinson’s disease between 45 years and 60 years old, 
which is outside our early-onset Parkinson’s disease 
cutoﬀ  age. These two factors probably resulted in a 
substantial underestimate of the prevalence of a 22q11.2 
deletion in early-onset Parkinson’s disease. Mortality is 
high in children with chromosome 22q11.2 deletion 
syndrome39,40 and also in carriers surviving into 
adulthood.41 In a report by Butcher,14 few patients with 
chromosome 22q11.2 deletion syndrome developed 
Parkinson’s disease, which suggests that other important 
modifying factors have a role in the penetrance of 
Parkinson’s disease among chromosome 22q11.2 
deletion syndrome. Last, but not least, early-onset 
Parkinson’s disease is uncommon. Underestimation of 
the prevalence of 22q11.2 deletion among people with 
Parkinson’s disease, increased mortality of 22q11.2 
deletion carriers, and non-penetrance of 22q11.2 deletion 
contribute to the discrepancy between the prevalence of 
chromosome 22q11.2 deletion syndrome overall and in 
people with early-onset Parkinson’s disease who carry 
the 22q11.2 deletion. 
Drug-induced dyskinesia and cognitive changes in 
people with Parkinson’s disease who have the 22q11.2 
deletion might be related to the underlying pathogenic 
mechanism (eg, perhaps related to a change in catechol-O-
methyltransferase [COMT] concentration secondary to 
loss of one copy of the COMT gene located within the 
chromosome 22q11.2 region). Alternatively, it might be 
resulted from a combination of early age at onset of 
Parkinson’s disease, disease duration, and COMT 
deﬁ ciency.  
How heterozygous microdeletions on chromosome 
22q11.2 lead to the diverse spectrum of associated 
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phenotypes is not well understood. Therefore, the 
pathogenic mechanisms that confer an increased risk of 
Parkinson’s disease warrant particular attention. 
 Parkinson’s disease is probably caused by haplo-
insuﬃ  ciency of one or more dose-sensitive genes within 
the deleted region. A second, as yet unidentiﬁ ed, 
recessive mutation in the remaining hemizygous allele 
within 22q11.2 might also contribute to  Parkinson’s 
disease. Finally, a 22q11.2 deletion might result in 
alteration of position eﬀ ects.42
So far, probably because of the paucity of appropriate 
tissue samples, the eﬀ ect of hemizygosity on gene 
expression in neural tissue from patients with 
chromosome 22q11.2 deletion syndrome has not been 
investigated.  Instead, gene expression has been 
investigated in blood cells using expression arrays and 
these have shown that many genes spanned by deletions 
at 22q11.2 have reduced expression in deletion carriers.43,44 
 Located within the 1·5 Mb region deleted in 22q11DS, 
the COMT gene is a strong candidate for Parkinson’s 
disease because it encodes an enzyme that degrades 
catecholamines, including dopamine, which is 
therapeutically relevant to Parkinson’s disease. Although 
Parkinson’s disease is not regarded as a disorder of 
dopamine metabolism, the identiﬁ cation that 
GCH1 mutations can lead to Parkinson’s disease as well 
as dopa-responsive dystonia suggests that biochemical 
depletion of dopamine is likely to have more complicated 
eﬀ ects than once thought.45 Findings from expression 
array studies using blood cells43,44 showed decreased 
COMT mRNA expression among patients with 
chromosome 22q11.2 deletion syndrome compared with 
controls. However, this ﬁ nding cannot be directly equated 
to decreased enzymatic activity of COMT. The activity in 
the brain is further complicated by the presence of the 
membrane-bound COMT isoform. In a meta-analysis of 
a well-characterised functional non-synonymous COMT 
polymorphism, rs4680 (Val158Met),46 no evidence was 
found for an increased risk of Parkinson’s disease. 
Therefore, further work is needed to assess 
comprehensively the possible relation between hemi-
zygosity of 22q11.2 deletion, long-term COMT deﬁ ciency, 
and clinical presentations in chromosome 22q11.2 
deletion syndrome.
In our analysis, we excluded a patient who carried the 
atypical 726 kb deletion (patient UK 3) because the deletion 
in that narrow region was not reported to be associated 
with chromosome 22q11.2 deletion syndrome. However, 
we cannot exclude the possibility that this deletion could 
suggest a minimal region of relevance for Parkinson’s 
disease (ie, the smallest genomic region in which a 
deletion leads to development of Parkinson’s disease). 
This study has several limitations. We did a 
retrospective combined analysis of four studies, which 
could be non-homogeneous. The methods of case 
referral might also have resulted in an ascertainment 
bias. A history of schizoaﬀ ective disorder was not an 
explicit exclusion criterion in the recruitment of patients 
with Parkinson’s disease, and although it is not part of 
the UK Brain Bank exclusion criteria, the UK Brain 
Bank does exclude patients having neuroleptic 
treatment at the onset of symptoms of Parkinson’s 
disease. Moreover, since 22q11.2 deletion carriers with 
severe psychiatric or other systemic illness, or both, 
would probably be managed by a psychiatrist and other 
specialists, they are less likely to have been referred to 
neurology recruitment centres and therefore are more 
likely to have been excluded from the study. This 
ascertainment bias would have lowered the percentage 
of 22q11.2 deletion carriers in the Parkinson’s disease 
cohorts. Thus, in this study, 0·49% of patients with 
early-onset Parkinson’s disease probably represents the 
lower limit of the prevalence of 22q11.2 deletions in 
early-onset Parkinson’s disease.
We also recognise that variation in recruitment criteria 
of the control groups could have aﬀ ected the low rate of 
22q11.2 deletion carriers identiﬁ ed. For example, 
although unselected population controls were used in 
the UK sample, people with schizophrenia were excluded 
from the Coriell controls in the US sample. Therefore, 
this exclusion might have resulted in a decreased 
frequency of 22q11.2 deletions in controls and an artiﬁ cial 
increase in the association. Based on an estimated 
prevalence of schizophrenia of 3·3% in a meta-analysis 
of 188 cohorts,47 and an estimated 1% prevalence of 
chromosome 22q11.2 deletion syndrome among people 
with schizophrenia (meta-analysis and community 
data),25,27 less than one case of chromosome 
22q11.2 deletion syndrome (0·24) would be detected in 
the Coriell controls (n=726) if schizophrenia was not 
excluded. Therefore, we believe that the eﬀ ect of 
excluding people with schizophrenia in the Coriell 
controls had little eﬀ ect on our results and is unlikely to 
have aﬀ ected the ﬁ nal conclusion. 
Additionally, participation of psychiatric patients might 
have been reduced in the control groups in this study, 
which could have resulted in an artiﬁ cially reduced 
prevalence of 22q11.2 deletions. However, our ﬁ nding 
was still signiﬁ cant when we made the comparison with 
the reported population frequency. In view of the high 
early mortality in chromosome 22q11.2 deletion 
syndrome (around 25% before age 40 years, as mentioned 
earlier), our population frequency of 0·024% might have 
been an overestimate and the p value might therefore 
have been underestimated. 
A further limitation is that the four genome-wide 
association studies were cross-sectional studies, rather 
than prospective studies, and we could only retrospectively 
trace the clinical details from medical records of the 
deletion carriers. Not all of the patients had received long-
term follow-up or had been assessed for progression 
systematically. Moreover, we did not have access to 
comprehensive clinical data and cannot conclusively 
exclude the possibility of the use of neuroleptics before 
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referral. Therefore, although we cannot rule out the 
possibility that treatment of psychiatric symptoms in 
some 22q11.2 deletion carriers could have led to the 
development of drug-induced parkinsonism, we are not 
aware of any of the eight deletion carriers having a severe 
psychiatric illness before ascertainment, and in view of 
the positive dopamine transporter scans for the four 
available patients and the positive response to levodopa or 
dopamine agonists for ﬁ ve of six patients, we believe that 
this is unlikely. Because of scarce detailed clinical data, we 
conﬁ ned our analyses to simple, but robust, phenotypes 
(eg, age at onset).
In conclusion, we provide evidence that deletions at 
22q11.2 increase the risk of Parkinson’s disease, particularly 
the early-onset form. In view of the strong association 
between the well-characterised 22q11.2 deletion and 
schizophrenia, clinicians should be aware of the possibility 
that a 22q11.2 deletion might underlie Parkinson’s disease 
with early presentation, psychiatric features, or other 
associated features, or a combination thereof. Under-
standing the mechanisms behind this dichotomy could 
give important insights into both developmental 
neurophysiology and disease pathogenesis. The precise 
biological mechanisms and whether additional genetic or 
epigenetic factors play a part in the increased risk of 
Parkinson’s disease among 22q11.2 deletion carriers 
should be addressed in future studies.
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